Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer-Reference-Cited by-同舟云学术

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer

Published:2019-07-16 Issue:590 Volume:12 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Blake Devon R.¹^ORCID,Vaseva Angelina V.²,Hodge Richard G.²^ORCID,Kline McKenzie P.³,Gilbert Thomas S. K.¹⁴^ORCID,Tyagi Vikas⁵^ORCID,Huang Daowei⁵^ORCID,Whiten Gabrielle C.⁵^ORCID,Larson Jacob E.⁵,Wang Xiaodong²⁵^ORCID,Pearce Kenneth H.⁵^ORCID,Herring Laura E.¹⁴^ORCID,Graves Lee M.¹²⁴,Frye Stephen V.²⁵^ORCID,Emanuele Michael J.¹²,Cox Adrienne D.¹²⁶^ORCID,Der Channing J.¹²^ORCID

Affiliation:

1. Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

3. Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

4. UNC Michael Hooker Proteomics Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

5. Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

6. Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Abstract

CDK9 inhibitors may treat KRAS-mutant cancers by inducing MYC protein degradation.

Funder

U.S. Department of Defense

American Cancer Society

National Cancer Institute

Pancreatic Cancer Action Network

Lustgarten Foundation

Debbie’s Dream Foundation

Publisher

American Association for the Advancement of Science (AAAS)